Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
French pharma firm Sanofi to buyback up to €2 billion in shares
French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 billion), to be completed between now and the end of December 2025. Sanofi has signed a mandate with an investment service provider for the second tranche.
Sanofi To Repurchase EUR 2 Bln Worth Of Shares
Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share
L’Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Sanofi Buys Back Shares From L’Oréal
PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.
Sanofi: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi
Press Release: Sanofi announces buy back of shares from L’Oréal
Sanofi announces buy back of shares from L’OréalParis, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from
L’Oreal Sells €3 Billion of Sanofi Stock to Drugmaker
Cosmetics company L’Oreal SA is selling a €3 billion ($3.1 billion) stake in Sanofi back to the French drugmaker, cashing in part of its holding after Sanofi’s shares outperformed the market over the past year.
French pharma Sanofi to repurchase L'Oréal shares
French pharmaceutical company Sanofi said on Monday that it plans to buy back shares from cosmetics firm L'Oréal. Sanofi said the acquisition would be of 2.3% of its shares from L'Oréal. This transaction is part of a share buyback programme announced on January 30,
FiercePharma13h
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Pharmabiz2h
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
policymed.com2d
Sanofi Sues HHS Over 340B Changes
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
FiercePharma7d
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
FierceBiotech3d
Sanofi-backed AdvanCell secures $112M series C to fund targeted alpha radiopharma trial
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now
We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...
Sanofi stock price target raised to EUR6.50 by CFRA
CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...
Bredin, Cleary Guide Sanofi’s €3B Share Buyback From L’Oreal
In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...